This symposium will bring basic scientists and clinicians together to discuss the latest developments in Head & Neck Cancer research and therapy. The intention of this meeting is to promote interactions between clinicians and researchers from diverse disciplines and to work towards bridging the translational gap. The agenda for the symposium includes a keynote address by Dr. Robert Ferris, a poster session and four panel discussions on Immunotherapy: Checkpoint Regulation, Immunotherapy: Beyond Checkpoint Inhibitors, Precision Medicine Strategies for Cancer and the Microbiome, and Clinical Problems and Challenges. The symposium will build on the success of our last meeting, “Head & Neck Cancer Symposium: From Pathways to Therapy”.


This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and the Dana-Farber Cancer Institute. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Boston University School of Medicine designates this live activity for a maximum of 7.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



This activity is supported by an educational grant from Bristol-Myers Squibb.

Planning Committee


Robert Haddad, MD

Disease Center Leader, Head and Neck Oncology Program
Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School

Maria Kukuruzinska, PhD

Professor, Molecular & Cell Biology
Associate Dean for Research
Boston University Henry M. Goldman School of Dental Medicine

Course Director:

Andrew Salama, DDS, MD, FACS
Assistant Professor, Oral & Maxillofacial Surgery
Director, Advanced Specialty Education Program in Oral & Maxillofacial Surgery
Boston University Henry M. Goldman School of Dental Medicine